Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | SMO | Q99835 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.44 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999279 | 0.87 | PARP10 (0.57) | ALOX5APPARP10MAPK14SMONPC1 | |
| SCHEMBL2989774 | 0.86 | PARP10 (0.50) | PARP10DRD4SLC6A5MAPK14SMO | |
| SCHEMBL14008636 | 0.85 | ALOX5AP (0.53) | ALOX5APPARP10MAPK14SMONPC1 | |
| SCHEMBL2248223 | 0.85 | ALOX5AP (0.55) | ALOX5APPARP10MAPK14SMORAB9A | |
| SCHEMBL3000832 | 0.85 | ALOX5AP (0.56) | ALOX5APPARP10MAPK14SMOSMN1; SMN2 | |
| SCHEMBL3000149 | 0.85 | ALOX5AP (0.56) | ALOX5APPARP10MAPK14SMONPC1 | |
| SCHEMBL2993311 | 0.85 | ALOX5AP (0.51) | ALOX5APPARP10MAPK14SMONPC1 | |
| SCHEMBL2993276 | 0.83 | PARP10 (0.52) | PARP10DRD4MAPK14SMONPC1 | |
| SCHEMBL2996721 | 0.83 | ALOX5AP (0.52) | ALOX5APPARP10MAPK14SMOSMN1; SMN2 | |
| SCHEMBL13267977 | 0.83 | ALOX5AP (0.51) | ALOX5APPARP10MAPK14SMOSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546232-A1 | Diphenyl Substituted Alkanes | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-29 | — | — | US | disclosed |
| EP-2170065-A1 | DIPHENYL SUBSTITUTED ALKANES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | ALOX5AP 15/4885PARP10 1048/4885DRD4 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.